73 related articles for article (PubMed ID: 1776852)
1. Prognostic indices in endometrial adenocarcinoma stages I and II. A study based on clinical, histopathological and flow cytometric variables.
Wagenius G; Strang P; Bergström R; Stendahl U; Tribukait B
Anticancer Res; 1991; 11(6):2137-42. PubMed ID: 1776852
[TBL] [Abstract][Full Text] [Related]
2. Prognostic index models in stage I and II endometrial carcinoma.
Nordström B; Bergström R; Strang P
Anticancer Res; 1998; 18(5B):3717-24. PubMed ID: 9854483
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of flow cytometric and clinical variables in endometrial adenocarcinoma stages I and II.
Wagenius G; Bergström R; Strang P; Gerdes U; Rogo K; Tribukait B; Stendahl U
Anticancer Res; 1992; 12(3):725-32. PubMed ID: 1622130
[TBL] [Abstract][Full Text] [Related]
4. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
5. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometrical DNA- and clinical parameters in the prediction of prognosis in stage I-II endometrial carcinoma.
Lindahl B; Gullberg B
Anticancer Res; 1991; 11(1):397-401. PubMed ID: 2018376
[TBL] [Abstract][Full Text] [Related]
7. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
[TBL] [Abstract][Full Text] [Related]
8. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of cell kinetics in endometrial adenocarcinoma.
Mariani L; Conti L; Antenucci A; Vercillo M; Atlante M; Gandolfo GM
Anticancer Res; 2000; 20(5B):3569-74. PubMed ID: 11131664
[TBL] [Abstract][Full Text] [Related]
10. Prospective malignancy grading, flow cytometry DNA-measurements and adjuvant chemotherapy for invasive squamous cell carcinoma of the uterine cervix.
Willén R; Himmelmann A; Långström-Einarsson E; Fernö M; Ranstam J; Baldetorp B; Skjaerris J; Prien-Larsen J; Tropé C; Stendahl U
Anticancer Res; 1993; 13(4):1187-96. PubMed ID: 8352543
[TBL] [Abstract][Full Text] [Related]
11. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
12. The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.
Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; Mychalczak BR; McKee B; Hoskins WJ; Barakat RR
Cancer; 2002 Jul; 95(2):316-21. PubMed ID: 12124832
[TBL] [Abstract][Full Text] [Related]
13. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
[TBL] [Abstract][Full Text] [Related]
14. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium.
Carey MS; O'Connell GJ; Johanson CR; Goodyear MD; Murphy KJ; Daya DM; Schepansky A; Peloquin A; Lumsden BJ
Gynecol Oncol; 1995 May; 57(2):138-44. PubMed ID: 7729725
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II: a prospective 5-year survival study.
Friberg LG; Norén H; Delle U
Gynecol Oncol; 1994 Apr; 53(1):64-9. PubMed ID: 8175025
[TBL] [Abstract][Full Text] [Related]
16. Residual myometrial invasion after intracavitary irradiation of endometrial adenocarcinoma stages I and II. Relations to DNA content and S-phase rate.
Wagenius G; Strang P; Boman K; Tribukait B; Stendahl U
In Vivo; 1988; 2(3-4):243-5. PubMed ID: 2979839
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
[TBL] [Abstract][Full Text] [Related]
18. DNA content as a prognostic factor in endometrial carcinoma.
Newbury R; Schuerch C; Goodspeed N; Fanning J; Glidewell O; Evans M
Obstet Gynecol; 1990 Aug; 76(2):251-7. PubMed ID: 2371030
[TBL] [Abstract][Full Text] [Related]
19. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma.
Baak JP; Snijders W; van Diermen B; van Diest PJ; Diepenhorst FW; Benraadt J
J Clin Oncol; 2003 Nov; 21(22):4214-21. PubMed ID: 14615450
[TBL] [Abstract][Full Text] [Related]
20. High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus.
Bonatz G; Frahm SO; Klapper W; Helfenstein A; Heidorn K; Jonat W; Krupp G; Parwaresch R; Rudolph P
Hum Pathol; 2001 Jun; 32(6):605-14. PubMed ID: 11431715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
